多発血管炎性肉芽腫症薬の世界市場レポート2020

• 英文タイトル：Global Granulomatosis with Polyangiitis Drug Sales Market Report 2020

• レポートコード：20QY06-07169 • 出版社/出版日：QYResearch / 2020年6月2日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、132ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品・医療

• 販売価格（消費税別）

Single User	￥592,000 (USD4,000)	▷ お問い合わせ
Multi User	￥888,000 (USD6,000)	▷ お問い合わせ
Enterprise License	￥1,184,000 (USD8,000)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社の当調査資料では、多発血管炎性肉芽腫症薬のグローバル市場について種類別（ベンラリズマブ、アバコパン、リツキシマブバイオシミラー、その他）、用途別（病院、クリニック、その他）、地域別（北米、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。 ・多発血管炎性肉芽腫症薬市場の概要 ・世界の主要地域別多発血管炎性肉芽腫症薬市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界の多発血管炎性肉芽腫症薬市場規模2015-2026：種類別（ベンラリズマブ、アバコパン、リツキシマブバイオシミラー、その他） ・世界の多発血管炎性肉芽腫症薬市場規模2015-2026：用途別（病院、クリニック、その他） ・多発血管炎性肉芽腫症薬の北米市場規模2015-2020 ・多発血管炎性肉芽腫症薬のヨーロッパ市場規模2015-2020 ・多発血管炎性肉芽腫症薬の中国市場規模2015-2020 ・多発血管炎性肉芽腫症薬の日本市場規模2015-2020 ・多発血管炎性肉芽腫症薬の東南アジア市場規模2015-2020 ・多発血管炎性肉芽腫症薬のインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 （Bionovis SA、Bristol-Myers Squibb Company、ChemoCentryx Inc、Coherus BioSciences Inc、Genor BioPharma Co Ltd、GlaxoSmithKline Plc、Iltoo Pharma、Panacea Biotec Ltd、Sandoz International GmbH、The International Biotechnology Center (IBC) Generium） ・多発血管炎性肉芽腫症薬の製造コスト分析 ・販売チャネル、流通業者、顧客 ・多発血管炎性肉芽腫症薬の市場動向・機会・課題 ・調査の結論

Market Analysis and Insights: Global Granulomatosis with Polyangiitis Drug Market
The global Granulomatosis with Polyangiitis Drug market was valued at US$ xx million in 2019 and will reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2020-2026.
Global Granulomatosis with Polyangiitis Drug Scope and Market Size
The global Granulomatosis with Polyangiitis Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Granulomatosis with Polyangiitis Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Granulomatosis with Polyangiitis Drug market is segmented into
Benralizumab
Avacopan
Rituximab Biosimilar
Others

Segment by Application, the Granulomatosis with Polyangiitis Drug market is segmented into
Hospital
Clinic
Others
The Granulomatosis with Polyangiitis Drug market is analysed and market size information is provided by regions (countries). Segment by Application, the Granulomatosis with Polyangiitis Drug market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Granulomatosis with Polyangiitis Drug Market Share Analysis
Granulomatosis with Polyangiitis Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Granulomatosis with Polyangiitis Drug business, the date to enter into the Granulomatosis with Polyangiitis Drug market, Granulomatosis with Polyangiitis Drug product introduction, recent developments, etc.
The major vendors covered:
Bionovis SA
Bristol-Myers Squibb Company
ChemoCentryx Inc
Coherus BioSciences Inc
Genor BioPharma Co Ltd
GlaxoSmithKline Plc
Iltoo Pharma
Panacea Biotec Ltd
Sandoz International GmbH
The International Biotechnology Center (IBC) Generium

レポート目次

---

Table of Contents

1 Granulomatosis with Polyangiitis Drug Market Overview
1.1 Granulomatosis with Polyangiitis Drug Product Scope
1.2 Granulomatosis with Polyangiitis Drug Segment by Type
1.2.1 Global Granulomatosis with Polyangiitis Drug Sales by Type (2020-2026)
1.2.2 Benralizumab
1.2.3 Avacopan
1.2.4 Rituximab Biosimilar
1.2.5 Others
1.3 Granulomatosis with Polyangiitis Drug Segment by Application
1.3.1 Global Granulomatosis with Polyangiitis Drug Sales Comparison by Application (2020-2026)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Granulomatosis with Polyangiitis Drug Market Estimates and Forecasts (2015-2026)
1.4.1 Global Granulomatosis with Polyangiitis Drug Sales Growth Rate (2015-2026)
1.4.2 Global Granulomatosis with Polyangiitis Drug Revenue and Growth Rate (2015-2026)
1.4.3 Global Granulomatosis with Polyangiitis Drug Price Trends (2015-2026)

2 Granulomatosis with Polyangiitis Drug Estimate and Forecast by Region
2.1 Global Granulomatosis with Polyangiitis Drug Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Granulomatosis with Polyangiitis Drug Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Region (2015-2020)
2.2.2 Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Region (2015-2020)
2.3 Global Granulomatosis with Polyangiitis Drug Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Granulomatosis with Polyangiitis Drug Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Granulomatosis with Polyangiitis Drug Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Granulomatosis with Polyangiitis Drug Estimates and Projections (2015-2026)
2.4.2 Europe Granulomatosis with Polyangiitis Drug Estimates and Projections (2015-2026)
2.4.3 China Granulomatosis with Polyangiitis Drug Estimates and Projections (2015-2026)
2.4.4 Japan Granulomatosis with Polyangiitis Drug Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Granulomatosis with Polyangiitis Drug Estimates and Projections (2015-2026)
2.4.6 India Granulomatosis with Polyangiitis Drug Estimates and Projections (2015-2026)
3 Global Granulomatosis with Polyangiitis Drug Competition Landscape by Players
3.1 Global Top Granulomatosis with Polyangiitis Drug Players by Sales (2015-2020)
3.2 Global Top Granulomatosis with Polyangiitis Drug Players by Revenue (2015-2020)
3.3 Global Granulomatosis with Polyangiitis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Granulomatosis with Polyangiitis Drug as of 2019)
3.4 Global Granulomatosis with Polyangiitis Drug Average Price by Company (2015-2020)
3.5 Manufacturers Granulomatosis with Polyangiitis Drug Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Granulomatosis with Polyangiitis Drug Players (Opinion Leaders)
4 Global Granulomatosis with Polyangiitis Drug Market Size by Type
4.1 Global Granulomatosis with Polyangiitis Drug Historic Market Review by Type (2015-2020)
4.1.1 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2015-2020)
4.1.2 Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2015-2020)
4.1.3 Global Granulomatosis with Polyangiitis Drug Price by Type (2014-2020)
4.2 Global Granulomatosis with Polyangiitis Drug Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Granulomatosis with Polyangiitis Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Granulomatosis with Polyangiitis Drug Revenue Forecast by Type (2021-2026)
4.2.3 Global Granulomatosis with Polyangiitis Drug Price Forecast by Type (2021-2026)
5 Global Granulomatosis with Polyangiitis Drug Market Size by Application
5.1 Global Granulomatosis with Polyangiitis Drug Historic Market Review by Application (2015-2020)
5.1.1 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2015-2020)
5.1.2 Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2015-2020)
5.1.3 Global Granulomatosis with Polyangiitis Drug Price by Application (2015-2020)
5.2 Global Granulomatosis with Polyangiitis Drug Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Granulomatosis with Polyangiitis Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Granulomatosis with Polyangiitis Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Granulomatosis with Polyangiitis Drug Price Forecast by Application (2021-2026)

3 North America Granulomatosis with Polyangiitis Drug Market Facts & Figures
3.2 North America Granulomatosis with Polyangiitis Drug Sales Market Share by Company (2015-2020)
3.3 North America Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2015-2020)
3.4 North America Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2015-2020)

4 Europe Granulomatosis with Polyangiitis Drug Market Facts & Figures
4.2 Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Company (2015-2020)
4.3 Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2015-2020)
4.4 Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2015-2020)

5 China Granulomatosis with Polyangiitis Drug Market Facts & Figures
5.2 China Granulomatosis with Polyangiitis Drug Sales Market Share by Company (2015-2020)
5.3 China Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2015-2020)
5.4 China Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2015-2020)

6 Japan Granulomatosis with Polyangiitis Drug Market Facts & Figures
6.2 Japan Granulomatosis with Polyangiitis Drug Sales Market Share by Company (2015-2020)
6.3 Japan Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2015-2020)
6.4 Japan Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2015-2020)

7 Southeast Asia Granulomatosis with Polyangiitis Drug Market Facts & Figures
7.2 Southeast Asia Granulomatosis with Polyangiitis Drug Sales Market Share by Company (2015-2020)
7.3 Southeast Asia Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2015-2020)
7.4 Southeast Asia Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2015-2020)

8 India Granulomatosis with Polyangiitis Drug Market Facts & Figures
8.2 India Granulomatosis with Polyangiitis Drug Sales Market Share by Company (2015-2020)
8.3 India Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2015-2020)
8.4 India Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2015-2020)

12 Company Profiles and Key Figures in Granulomatosis with Polyangiitis Drug Business
12.1 Bionovis SA
12.1.1 Bionovis SA Granulomatosis with Polyangiitis Drug Corporation Information
12.1.2 Bionovis SA Granulomatosis with Polyangiitis Drug Business Overview and Total Revenue
12.1.3 Bionovis SA Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Bionovis SA Granulomatosis with Polyangiitis Drug Products Offered
12.1.5 Bionovis SA Recent Development
12.2 Bristol-Myers Squibb Company
12.2.1 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Corporation Information
12.2.2 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Business Overview and Total Revenue
12.2.3 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Products Offered
12.2.5 Bristol-Myers Squibb Company Recent Development
12.3 ChemoCentryx Inc
12.3.1 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Corporation Information
12.3.2 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Business Overview and Total Revenue
12.3.3 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2015-2020)
12.3.4 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Products Offered
12.3.5 ChemoCentryx Inc Recent Development
12.4 Coherus BioSciences Inc
12.4.1 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Corporation Information
12.4.2 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Business Overview and Total Revenue
12.4.3 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Products Offered
12.4.5 Coherus BioSciences Inc Recent Development
12.5 Genor BioPharma Co Ltd
12.5.1 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Corporation Information
12.5.2 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Business Overview and Total Revenue
12.5.3 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Products Offered
12.5.5 Genor BioPharma Co Ltd Recent Development
12.6 GlaxoSmithKline Plc
12.6.1 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Corporation Information
12.6.2 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Business Overview and Total Revenue
12.6.3 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2015-2020)
12.6.4 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Products Offered
12.6.5 GlaxoSmithKline Plc Recent Development
12.7 Iltoo Pharma
12.7.1 Iltoo Pharma Granulomatosis with Polyangiitis Drug Corporation Information
12.7.2 Iltoo Pharma Granulomatosis with Polyangiitis Drug Business Overview and Total Revenue
12.7.3 Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Iltoo Pharma Granulomatosis with Polyangiitis Drug Products Offered
12.7.5 Iltoo Pharma Recent Development
12.8 Panacea Biotec Ltd
12.8.1 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Corporation Information
12.8.2 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Business Overview and Total Revenue
12.8.3 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Products Offered
12.8.5 Panacea Biotec Ltd Recent Development
12.9 Sandoz International GmbH
12.9.1 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Corporation Information
12.9.2 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Business Overview and Total Revenue
12.9.3 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2015-2020)
12.9.4 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Products Offered
12.9.5 Sandoz International GmbH Recent Development
12.10 The International Biotechnology Center (IBC) Generium
12.10.1 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Corporation Information
12.10.2 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Business Overview and Total Revenue
12.10.3 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2015-2020)
12.10.4 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Products Offered
12.10.5 The International Biotechnology Center (IBC) Generium Recent Development

13 Granulomatosis with Polyangiitis Drug Manufacturing Cost Analysis
13.1 Granulomatosis with Polyangiitis Drug Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Granulomatosis with Polyangiitis Drug
13.4 Granulomatosis with Polyangiitis Drug Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Granulomatosis with Polyangiitis Drug Distributors List
14.3 Granulomatosis with Polyangiitis Drug Customers

15 Market Dynamics
15.1 Market Trends
15.2 Opportunities and Drivers
15.3 Challenges
15.4 Porter’s Five Forces Analysis

16 Research Findings and Conclusion

17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer

List of Tables

Table 1. Global Granulomatosis with Polyangiitis Drug Sales (K Pcs) Growth Rate by Type (2020-2026)
Table 2. Global Granulomatosis with Polyangiitis Drug Sales (K Pcs) Comparison by Application (2020-2026)
Table 3. Global Market Granulomatosis with Polyangiitis Drug Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 4. Global Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Region (2015-2020)
Table 5. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Region (2015-2020)
Table 6. Global Granulomatosis with Polyangiitis Drug Revenue (US$ Million) Market Share by Region (2015-2020))
Table 7. Global Granulomatosis with Polyangiitis Drug Revenue Share by Region (2015-2020)
Table 8. Global Granulomatosis with Polyangiitis Drug Sales (K Pcs) Forecast by Region (2021-2026)
Table 9. Global Granulomatosis with Polyangiitis Drug Sales Market Share Forecast by Region (2021-2026)
Table 10. Global Granulomatosis with Polyangiitis Drug Revenue (US$ Million) Forecast by Region (2021-2026)
Table 11. Global Granulomatosis with Polyangiitis Drug Revenue Share Forecast by Region (2021-2026)
Table 12. Global Granulomatosis with Polyangiitis Drug (K Pcs) of Key Companies (2015-2020)
Table 13. Global Granulomatosis with Polyangiitis Drug Sales Share by Company (2015-2020)
Table 14. Global Granulomatosis with Polyangiitis Drug Revenue (US$ Million) by Company (2015-2020)
Table 15. Global Granulomatosis with Polyangiitis Drug Revenue Share by Company (2015-2020)
Table 16. Global Granulomatosis with Polyangiitis Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Granulomatosis with Polyangiitis Drug as of 2019)
Table 17. Global Granulomatosis with Polyangiitis Drug Average Price (USD/Pcs) of Key Company (2015-2020)
Table 18. Manufacturers Granulomatosis with Polyangiitis Drug Manufacturing Sites and Area Served
Table 19. Manufacturers Granulomatosis with Polyangiitis Drug Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Main Points Interviewed from Key Granulomatosis with Polyangiitis Drug Players
Table 22. Global Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Type (2015-2020)
Table 23. Global Granulomatosis with Polyangiitis Drug Sales Share by Type (2015-2020)
Table 24. Global Granulomatosis with Polyangiitis Drug Revenue (US$ Million) Market Share by Type (2015-2020)
Table 25. Global Granulomatosis with Polyangiitis Drug Price (K Pcs) by Type (2015-2020)
Table 26. Global Granulomatosis with Polyangiitis Drug Sales Share by Type (2021-2026)
Table 27. Global Granulomatosis with Polyangiitis Drug Revenue (US$ Million) Market Share by Type (2021-2026)
Table 28. Global Granulomatosis with Polyangiitis Drug Revenue Share by Type (2021-2026)
Table 29. Global Granulomatosis with Polyangiitis Drug Price (K Pcs) by Type (2021-2026)
Table 30. Global Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Application (2015-2020)
Table 31. Global Granulomatosis with Polyangiitis Drug Sales Share by Application (2015-2020)
Table 32. Global Granulomatosis with Polyangiitis Drug Revenue (US$ Million) Market Share by Application (2015-2020)
Table 33. Global Granulomatosis with Polyangiitis Drug Price (K Pcs) by Application (2015-2020)
Table 34. Global Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Application (2021-2026)
Table 35. Global Granulomatosis with Polyangiitis Drug Sales Share by Application (2021-2026)
Table 36. Global Granulomatosis with Polyangiitis Drug Revenue (US$ Million) Market Share by Application (2021-2026)
Table 37. Global Granulomatosis with Polyangiitis Drug Revenue Share by Application (2021-2026)
Table 38. Global Granulomatosis with Polyangiitis Drug Price (K Pcs) by Application (2021-2026)
Table 39. United States Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Company (2015-2020)
Table 40. United States Granulomatosis with Polyangiitis Drug Sales Market Share by Company (2015-2020)
Table 41. United States Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Type (2015-2020)
Table 42. United States Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2015-2020)
Table 43. United States Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Application (2015-2020)
Table 44. United States Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2015-2020)
Table 45. Europe Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Company (2015-2020)
Table 46. Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Company (2015-2020)
Table 47. Europe Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Type (2015-2020)
Table 48. Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2015-2020)
Table 49. Europe Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Application (2015-2020)
Table 50. Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2015-2020)
Table 51. China Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Company (2015-2020)
Table 52. China Granulomatosis with Polyangiitis Drug Sales Market Share by Company (2015-2020)
Table 53. China Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Type (2015-2020)
Table 54. China Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2015-2020)
Table 55. China Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Application (2015-2020)
Table 56. China Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2015-2020)
Table 57. Japan Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Company (2015-2020)
Table 58. Japan Granulomatosis with Polyangiitis Drug Sales Market Share by Company (2015-2020)
Table 59. Japan Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Type (2015-2020)
Table 60. Japan Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2015-2020)
Table 61. Japan Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Application (2015-2020)
Table 62. Japan Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2015-2020)
Table 63. Southeast Asia Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Company (2015-2020)
Table 64. Southeast Asia Granulomatosis with Polyangiitis Drug Sales Market Share by Company (2015-2020)
Table 65. Southeast Asia Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Type (2015-2020)
Table 66. Southeast Asia Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2015-2020)
Table 67. Southeast Asia Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Type (2015-2020)
Table 68. Southeast Asia Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2015-2020)
Table 69. India Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Company (2015-2020)
Table 70. India Granulomatosis with Polyangiitis Drug Sales Market Share by Company (2015-2020)
Table 71. India Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Type (2015-2020)
Table 72. India Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2015-2020)
Table 73. India Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Application (2015-2020)
Table 74. India Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2015-2020)
Table 75. Bionovis SA Corporation Information
Table 76. Bionovis SA Description and Business Overview
Table 77. Bionovis SA Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 78. Bionovis SA Granulomatosis with Polyangiitis Drug Product
Table 79. Bionovis SA Recent Development
Table 80. Bristol-Myers Squibb Company Corporation Information
Table 81. Bristol-Myers Squibb Company Description and Business Overview
Table 82. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 83. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product
Table 84. Bristol-Myers Squibb Company Recent Development
Table 85. ChemoCentryx Inc Corporation Information
Table 86. ChemoCentryx Inc Description and Business Overview
Table 87. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 88. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product
Table 89. ChemoCentryx Inc Recent Development
Table 90. Coherus BioSciences Inc Corporation Information
Table 91. Coherus BioSciences Inc Description and Business Overview
Table 92. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 93. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product
Table 94. Coherus BioSciences Inc Recent Development
Table 95. Genor BioPharma Co Ltd Corporation Information
Table 96. Genor BioPharma Co Ltd Description and Business Overview
Table 97. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 98. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product
Table 99. Genor BioPharma Co Ltd Recent Development
Table 100. GlaxoSmithKline Plc Corporation Information
Table 101. GlaxoSmithKline Plc Description and Business Overview
Table 102. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 103. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product
Table 104. GlaxoSmithKline Plc Recent Development
Table 105. Iltoo Pharma Corporation Information
Table 106. Iltoo Pharma Description and Business Overview
Table 107. Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 108. Iltoo Pharma Granulomatosis with Polyangiitis Drug Product
Table 109. Iltoo Pharma Recent Development
Table 110. Panacea Biotec Ltd Corporation Information
Table 111. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 112. Panacea Biotec Ltd Description and Business Overview
Table 113. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product
Table 114. Panacea Biotec Ltd Recent Development
Table 115. Sandoz International GmbH Corporation Information
Table 116. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 117. Sandoz International GmbH Description and Business Overview
Table 118. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product
Table 119. Sandoz International GmbH Recent Development
Table 120. The International Biotechnology Center (IBC) Generium Corporation Information
Table 121. The International Biotechnology Center (IBC) Generium Description and Business Overview
Table 122. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 123. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product
Table 124. The International Biotechnology Center (IBC) Generium Recent Development
Table 125. Production Base and Market Concentration Rate of Raw Material
Table 126. Key Suppliers of Raw Materials
Table 127. Granulomatosis with Polyangiitis Drug Distributors List
Table 128. Granulomatosis with Polyangiitis Drug Customers List
Table 129. Market Key Trends
Table 130. Key Opportunities and Drivers: Impact Analysis (2020-2026)
Table 131. Key Challenges
Table 132. Research Programs/Design for This Report
Table 133. Key Data Information from Secondary Sources
Table 134. Key Data Information from Primary Sources
List of Figures
Figure 1. Granulomatosis with Polyangiitis Drug Product Picture
Figure 2. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Granulomatosis with Polyangiitis Drug Market Share by Application in 2020 & 2026
Figure 6. Hospital Examples
Figure 7. Clinic Examples
Figure 8. Others Examples
Figure 9. Global Granulomatosis with Polyangiitis Drug Sales (K Pcs) Growth Rate (2015-2026)
Figure 10. Global Granulomatosis with Polyangiitis Drug Revenue (US$ Million) Growth Rate (2015-2026)
Figure 11. Global Granulomatosis with Polyangiitis Drug Price Trends Growth Rate (2015-2026) (USD/Pcs)
Figure 12. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Region: 2015 VS 2020
Figure 13. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Region: 2021 VS 2026
Figure 14. United States Granulomatosis with Polyangiitis Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 15. United States Granulomatosis with Polyangiitis Drug Sales (K Pcs) Growth Rate (2015-2026)
Figure 16. Europe Granulomatosis with Polyangiitis Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 17. Europe Granulomatosis with Polyangiitis Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 18. China Granulomatosis with Polyangiitis Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 19. China Granulomatosis with Polyangiitis Drug Sales (Million USD) and Growth Rate (2015-2026)
Figure 20. Japan Granulomatosis with Polyangiitis Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 21. Japan Granulomatosis with Polyangiitis Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 22. Southeast Asia Granulomatosis with Polyangiitis Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 23. Southeast Asia Granulomatosis with Polyangiitis Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 24. India Granulomatosis with Polyangiitis Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 25. India Granulomatosis with Polyangiitis Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 26. Global 5 Largest Granulomatosis with Polyangiitis Drug Players Market Share by Revenue in Granulomatosis with Polyangiitis Drug 2015 & 2019
Figure 27. Granulomatosis with Polyangiitis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 28. Global Granulomatosis with Polyangiitis Drug Revenue Share by Type (2015-2020)
Figure 29. Global Granulomatosis with Polyangiitis Drug Revenue Growth Rate by Type in 2015 & 2019
Figure 30. Global Granulomatosis with Polyangiitis Drug Revenue Share by Application (2015-2020)
Figure 31. Global Granulomatosis with Polyangiitis Drug Revenue Growth Rate by Application in 2015 & 2019
Figure 32. United States Granulomatosis with Polyangiitis Drug Sales Market Share by Type in 2019
Figure 33. United States Granulomatosis with Polyangiitis Drug Sales Market Share by Type in 2019
Figure 34. Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Company in 2019
Figure 35. Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Type in 2019
Figure 36. Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Application in 2019
Figure 37. China Granulomatosis with Polyangiitis Drug Sales Market Share by Company in 2019
Figure 38. China Granulomatosis with Polyangiitis Drug Sales Market Share by Type in 2019
Figure 39. China Granulomatosis with Polyangiitis Drug Sales Market Share by Application in 2019
Figure 40. Japan Granulomatosis with Polyangiitis Drug Sales Market Share by Company in 2019
Figure 41. Japan Granulomatosis with Polyangiitis Drug Sales Market Share by Type in 2019
Figure 42. Japan Granulomatosis with Polyangiitis Drug Sales Market Share by Application in 2019
Figure 43. Southeast Asia Granulomatosis with Polyangiitis Drug Sales Market Share by Company in 2019
Figure 44. Southeast Asia Granulomatosis with Polyangiitis Drug Sales Market Share by Type in 2019
Figure 45. Southeast Asia Granulomatosis with Polyangiitis Drug Sales Market Share by Application in 2019
Figure 46. India Granulomatosis with Polyangiitis Drug Sales Market Share by Company in 2019
Figure 47. India Granulomatosis with Polyangiitis Drug Sales Market Share by Type in 2019
Figure 48. India Granulomatosis with Polyangiitis Drug Sales Market Share by Application in 2019
Figure 49. Bionovis SA Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. Bristol-Myers Squibb Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. ChemoCentryx Inc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Coherus BioSciences Inc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Genor BioPharma Co Ltd Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. GlaxoSmithKline Plc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Iltoo Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Panacea Biotec Ltd Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Sandoz International GmbH Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. The International Biotechnology Center (IBC) Generium Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. Key Raw Materials Price Trend
Figure 60. Manufacturing Cost Structure of Granulomatosis with Polyangiitis Drug
Figure 61. Manufacturing Process Analysis of Granulomatosis with Polyangiitis Drug
Figure 62. Granulomatosis with Polyangiitis Drug Industrial Chain Analysis
Figure 63. Channels of Distribution
Figure 64. Distributors Profiles
Figure 65. Porter's Five Forces Analysis
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed

---